
Resmed Inc
NYSE:RMD

Intrinsic Value
The intrinsic value of one
RMD
stock under the Base Case scenario is
196.23
USD.
Compared to the current market price of 241.95 USD,
Resmed Inc
is
Overvalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Resmed Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Resmed Inc
Balance Sheet Decomposition
Resmed Inc
Current Assets | 3.2B |
Cash & Short-Term Investments | 932.7m |
Receivables | 907.8m |
Other Current Assets | 1.4B |
Non-Current Assets | 4.4B |
PP&E | 687.9m |
Intangibles | 3.3B |
Other Non-Current Assets | 391.4m |
Free Cash Flow Analysis
Resmed Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Resmed Inc
Revenue
|
5B
USD
|
Cost of Revenue
|
-2.1B
USD
|
Gross Profit
|
3B
USD
|
Operating Expenses
|
-1.3B
USD
|
Operating Income
|
1.6B
USD
|
Other Expenses
|
-298.8m
USD
|
Net Income
|
1.3B
USD
|
RMD Profitability Score
Profitability Due Diligence
Resmed Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Score
Resmed Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
RMD Solvency Score
Solvency Due Diligence
Resmed Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Score
Resmed Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RMD Price Targets Summary
Resmed Inc
According to Wall Street analysts, the average 1-year price target for
RMD
is 265.77 USD
with a low forecast of 202 USD and a high forecast of 309.75 USD.
Dividends
Current shareholder yield for RMD is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RMD
stock under the Base Case scenario is
196.23
USD.
Compared to the current market price of 241.95 USD,
Resmed Inc
is
Overvalued by 19%.